Advertisement

Topics

Novartis: RTH258 Meets Endpoints In Two Phase III Studies

01:45 EDT 20 Jun 2017 | FinanzNachrichten

BASEL (dpa-AFX) - Novartis (NVS) reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two Phase III studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, al...

Original Article: Novartis: RTH258 Meets Endpoints In Two Phase III Studies

NEXT ARTICLE

More From BioPortfolio on "Novartis: RTH258 Meets Endpoints In Two Phase III Studies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...